Citations 1
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
Komrokji, Rami S. , Seymour, John F. , Roberts, Andrew W. , Wadleigh, Martha , To, Luen Bik, Scherber, Robyn M. , Turba, E , Dorr, Andrew, Zhu, Joy, Wang, Lixia , Granston, Tanya, Campbell, Mary S., Scherber, Robyn, Mesa, Ruben A. , Roberts, Andrew W , Komrokji, Rami S
Blood | March 11, 2015 | Volume: 125 | Issue: 17 | Pages: 2649-2655
Key Points Pacritinib reduced myelofibrosis-related splenomegaly and patient symptoms without causing clinically significant myelosuppression. Pacritinib had activity and was well tolerated in patients with preexisting anemia and thrombocytopenia.